Source-grounded facts extracted from INSMED Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INSMED Inc shareholders approved Ratification of the Appointment of an Independent Registered Public Accounting Firm at the 2026-05-13 meeting.
“By the following vote, shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026: For Against Abstentions 190,386,612 6,997,613 45,308”
INSMED Inc shareholders approved Advisory Vote on the 2025 Compensation of Named Executive Officers at the 2026-05-13 meeting.
“By the following vote, shareholders approved, on an advisory, non-binding basis, the 2025 compensation of our named executive officers, as disclosed in the Proxy Statement: For Against Abstentions Broker Non-Votes 162,133,728 23,657,325 74,398 11,564,082”
INSMED Inc shareholders approved Election of Two Class II Directors at the 2026-05-13 meeting.
“By the following votes, shareholders elected Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D., to serve as Class II directors until the Company’s 2029 Annual Meeting of Shareholders: For Withheld Broker Non-Votes Elizabeth McKee Anderson 153,734,471 32,130,980 11,564,082 Clarissa Desjardins, Ph.D. 164,437,828 21,427,623 11,564,082”
INSMED Inc reported the first quarter ended March 31, 2026 results: revenue $306.0 Million. Guidance reaffirmed.
“99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —”
J. Drayton Wise resigned as Chief Commercial Officer at INSMED Inc.
“On April 16, 2025, J. Drayton Wise notified Insmed Incorporated (the “Company”) of his decision to resign from his position as the Company’s Chief Commercial Officer for personal and medical reasons, effective immediately.”
Alfred Altomari departed as Director at INSMED Inc.
“On February 18, 2025, Alfred Altomari notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”).”
INSMED Inc shareholders approved Approval of Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.
“Proposal 4. Approval of Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan. By the following vote, shareholders approved Amendment No. 1 to the 2019 Incentive Plan: For Against Abstentions Broker Non-Votes 122,169,823 6,589,414 56,760 10,923,081”
INSMED Inc shareholders approved Ratification of the Appointment of an Independent Registered Public Accounting Firm at the 2024-12-31 meeting.
“Proposal 3. Ratification of the Appointment of an Independent Registered Public Accounting Firm. By the following vote, shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024: For Against Abstentions 135,507,026 4,170,279 61,773”
INSMED Inc shareholders approved Advisory Vote on the 2023 Compensation of Named Executive Officers.
“Proposal 2. Advisory Vote on the 2023 Compensation of Named Executive Officers. By the following vote, shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers, as disclosed in the Proxy Statement: For Against Abstentions Broker Non-Votes 120,643,045 8,076,144 96,808 10,923,081”
INSMED Inc shareholders approved Election of Four Class III Directors.
“Proposal 1. Election of Four Class III Directors. By the following votes, shareholders elected David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D. to serve as Class III directors until the Company’s 2027 Annual Meeting of Shareholders: For Withheld Broker Non-Votes David R. Brennan 120,537,761 8,278,236 10,923,081 Leo Lee 125,634,442 3,181,555 10,923,081 Carol A. Schafer 113,910,394 14,905,603 10,923,081 Melvin Sharoky, M.D. 117,140,717 11,675,280 10,923,081”
INSMED Inc updated its the first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 9, 2024, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the three months ended March 31, 2024.”
INSMED Inc reported financial results for the fourth quarter and full year ended December 31, 2023.
“On February 22, 2024, Insmed Incorporated issued a press release regarding its financial results for the three months and fiscal year ended December 31, 2023.”
INSMED Inc terminated Prior Agreement with Leerink Partners LLC (effective 2024-02-22).
“On February 22, 2024, in connection with entry into the Agreement described under Item 1.01 above, the Company and Leerink mutually agreed to terminate the Prior Agreement, which termination became effective on February 22, 2024.”
INSMED Inc entered into Sales Agreement with Leerink Partners LLC valued at up to $500,000,000 (effective 2024-02-22).
“On February 22, 2024, Insmed Incorporated (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC, as agent (“Leerink”), under which the Company may offer and sell its common stock, par value $0.01 per share, from time to time having an aggregate offering price of up to $500,000,000 (the “Shares”) during the term of the Agreement through Leerink, acting as agent.”
INSMED Inc reported the third quarter ended September 30, 2023 results: revenue $79.1 million. Guidance reaffirmed.
“Total revenue for the third quarter ended September 30, 2023 was $79.1 million”
INSMED Inc: Amended and restated bylaws to enhance disclosure and procedural requirements for shareholder nominations and to allow Board to designate number of directors (effective 2023-05-11).
“On May 11, 2023, the Board amended the Company’s Amended and Restated Bylaws to, among other things, (i) enhance disclosure and procedural requirements in connection with shareholder nominations of directors, including by (a) requiring any shareholder submitting a nomination notice to make a representation as to whether such shareholder intends to solicit proxies in support of director nominees other than the Company’s nominees in accordance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), (b) requiring nominating shareholders to provide reasonable evidence, on request of the Company, that certain requirements of such rule have been satisfied, (c) permitting the Company to disregard proxies or votes solicited for such shareholders’ nominees if such shareholder fails to comply with the requirements of Rule 14a-19(a)(2) and Rule 14a-19(a)(3) and (d) incorporating other technical changes in light of the universal proxy rules adopted by the Secur”
INSMED Inc shareholders approved Approval of the Insmed Incorporated Amended and Restated 2019 Incentive Plan.
“Proposal 5. Approval of the Insmed Incorporated Amended and Restated 2019 Incentive Plan. By the following vote, shareholders approved the 2019 Incentive Plan: For Against Abstentions Broker Non-Votes 101,645,357 11,014,232 57,362 10,061,166”
INSMED Inc shareholders approved Ratification of the Appointment of an Independent Registered Public Accounting Firm at the 2023-12-31 meeting.
“Proposal 4. Ratification of the Appointment of an Independent Registered Public Accounting Firm. By the following vote, shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023: For Against Abstentions 118,039,703 4,692,773 45,641”
INSMED Inc shareholders approved Advisory Vote on the Frequency of Future Shareholder Advisory Votes on the Compensation of Named Executive Officers.
“Proposal 3. Advisory Vote on the Frequency of Future Shareholder Advisory Votes on the Compensation of Named Executive Officers. By the following vote, shareholders voted, on an advisory, non-binding basis, to hold future advisory votes on the compensation of the Company’s named executive officers every [one year]: Every One Year Every Two Years Every Three Years Abstentions Broker Non-Votes 112,492,825 39,256 132,313 52,557 10,061,166”
INSMED Inc shareholders approved Advisory Vote on the 2022 Compensation of Named Executive Officers.
“Proposal 2. Advisory Vote on the 2022 Compensation of Named Executive Officers. By the following vote, shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers, as disclosed in the Proxy Statement: For Against Abstentions Broker Non-Votes 107,704,649 4,953,460 58,842 10,061,166”
INSMED Inc shareholders approved Election of Three Class II Directors.
“Proposal 1. Election of Three Class II Directors. By the following votes, shareholders elected Elizabeth McKee Anderson, Clarissa Desjardins, Ph.D. and David W.J. McGirr to serve as Class II directors until the Company’s 2026 Annual Meeting of Shareholders: For Withheld Broker Non-Votes Elizabeth McKee Anderson 87,802,723 24,914,228 10,061,166 Clarissa Desjardins, Ph.D. 100,205,259 12,511,692 10,061,166 David W.J. McGirr 99,507,941 13,209,010 10,061,166”
INSMED Inc reported the first quarter ended March 31, 2023 results: revenue $65.2 million. Guidance reaffirmed.
“Total revenue for the first quarter ended March 31, 2023, was $65.2 million, reflecting 23% year-over-year growth compared to total revenue of $53.1 million for the first quarter of 2022.”
INSMED Inc reported the full year ended December 31, 2022 results: revenue $245.4 million, net income net loss of $481.5 mill.
“Total revenue for the full year 2022 was $245.4 million, compared to total revenue of $188.5 million for the full year 2021.”
INSMED Inc reported the fourth quarter ended December 31, 2022 results: revenue $59.3 million, net income net loss of $160.1 million, EPS $1.21 per share.
“on Track to Share Topline Data from Post-Marketing ARISE Study of ARIKAYCE ® (amikacin liposome inhalation suspension) in Third Quarter of 2023— —ARIKAYCE Total Revenue of $59.3 Million for the Fourth Quarter and $245.4 Million for the Full Year 2022, Reflecting 30% Annual Growth— BRIDGEWATER, N.J., February 23, 2023 /PRNewswire/ — Insmed Incorporated”
INSMED Inc reported full-year 2022 results: revenue at least 30% year over year. Guidance reaffirmed.
“Insmed continues to expect full-year 2022 global revenues for ARIKAYCE to increase at least 30% year over year from 2021”
INSMED Inc reported three months ended September 30, 2022 results: net income $131.1 million, EPS $1.09.
“Insmed reported a net loss of $131.1 million, or $1.09 per share”
INSMED Inc reported three months and nine months ended September 30, 2022 results: revenue $67.7 million, net income $131.1 million, EPS $1.09. Guidance reaffirmed.
“Total revenue for the third quarter ended September 30, 2022, was $67.7 million”
Drayton Wise was appointed as Chief Commercial Officer at INSMED Inc.
“On May 23, 2022, Insmed Incorporated (the “Company”) announced that Mr. Drayton Wise has been appointed as Chief Commercial Officer of the Company, effective immediately.”
Steinar J. Engelsen departed as Director at INSMED Inc.
“On February 15, 2022, Steinar J. Engelsen, M.D. notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2022 Annual Meeting of Shareholders (the “Annual Meeting”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.